<h2>关键点</h2>
<ul>
<li>Embecta 最近的季度报告结果令人失望。</li>
<li>财政第二季度的销售和收益远低于预期。</li>
<li>在最新的季度报告后，Embecta 的前景似乎变得更加疲弱。</li>
<li>这 10 只股票可能会造就下一波百万富翁 ›</li>
</ul>
<p><strong>Embecta</strong>（NASDAQ: EMBC）股票在公司最新季度报告发布后于周二暴跌。该医疗设备公司的股价在日常交易中下跌了 57.8%。</p>
<p>今天早上市场开盘前，Embecta 发布了其 2026 财政年度第二季度的业绩——该季度于 3 月 31 日结束。公司的销售和收益显著低于预期，投资者对近期的未来并不乐观。</p>
<p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2ODgwMi9nZXR0eWltYWdlcy0xODE4NTUxMzU5LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2ODgwMi9nZXR0eWltYWdlcy0xODE4NTUxMzU5LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>Embecta 在财政第二季度出现重大失误</h2>
<p>在财政第二季度的报告中，Embecta 宣布非公认会计原则（调整后）每股收益为 0.27 美元，销售额为 2.218 亿美元。同时，平均分析师预期该公司每股调整后利润为 0.42 美元，销售额约为 2.357 亿美元。Embecta 的销售额在财政第二季度意外下降了 14.4%，利润率也显著低于预期。该公司在本季度记录的调整后息税折旧摊销前利润（EBITDA）利润率为 29.1%——低于去年同期的 37.5%。</p>
<h2>Embecta 的未来展望</h2>
<p>在财政第二季度的报告中，Embecta 将全年的销售指导下调至 10.15 亿至 10.35 亿美元——低于之前的销售指导 1.071 亿至 1.093 亿美元。虽然销售下调幅度看似不大，但却引发了对公司近期增长前景的质疑。同时，该公司的调整后营业利润率现在预计在 22.25% 至 23.25% 之间——相比之前的 29% 至 30% 的指导大幅降低。</p>
<p>该公司预计将完成对 Owen Mumford 的收购，并预计此次收购将对每股收益产生约 0.15 美元的稀释影响。虽然与收购相关的费用将对收益构成压力，但公司将调整后的每股收益指导从 2.80 至 3 美元下调至 1.55 至 1.75 美元，这对投资者提出了一些重大问题。</p>
<h2>现在投资 1000 美元的地方</h2>
<p>当我们的分析师团队有股票推荐时，听取建议是值得的。毕竟，<em>Stock Advisor</em> 的总平均回报率为 963%*——相比标普 500 的 201% 表现出色。</p>
<p>他们刚刚透露了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买，<strong>加入_Stock Advisor_ 时可获得。</strong></p>
<p><strong>查看股票 »</strong></p>
<p><em>*Stock Advisor 的回报截至 2026 年 5 月 5 日。</em></p>
<p><em>Keith Noonan 在提到的任何股票中没有持仓。Motley Fool 在提到的任何股票中没有持仓。Motley Fool 有披露政策。</em></p>
<p>此处表达的观点和意见是作者的观点和意见，并不一定反映纳斯达克公司的观点。</p>

EMBC

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Embecta 的股票在发布令人失望的 2023 财年第二季度报告后暴跌 57.8%。该公司调整后的每股收益为 0.27 美元，销售额为 2.218 亿美元，均未达到分析师预期的每股 0.42 美元和销售额 2.357 亿美元。公司还报告了 14.4% 的同比销售下降，并将全年销售指引下调至 10.15 亿至 10.35 亿美元，这引发了对其增长前景的担忧。此外，调整后的营业利润率预计将在 22.25% 至 23.25% 之间，低于之前 29% 至 30% 的预期</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>Embecta's recent quarterly report arrived with disappointing results.</li>
<li>Sales and earnings for fiscal Q2 came in far weaker than anticipated.</li>
<li>Embecta's outlook appears weaker following its latest quarterly report.</li>
<li>These 10 stocks could mint the next wave of millionaires ›</li>
</ul>
<div class="lb-trans"><ul>
<li>Embecta 最近的季度报告结果令人失望。</li>
<li>财政第二季度的销售和收益远低于预期。</li>
<li>在最新的季度报告后，Embecta 的前景似乎变得更加疲弱。</li>
<li>这 10 只股票可能会造就下一波百万富翁 ›</li>
</ul>
</div><p><strong>Embecta</strong>(NASDAQ: EMBC) stock crashed Tuesday following the company's latest quarterly report. The medical-device specialist's share price ended the daily session down 57.8%.</p>
<div class="lb-trans"><p><strong>Embecta</strong>（NASDAQ: EMBC）股票在公司最新季度报告发布后于周二暴跌。该医疗设备公司的股价在日常交易中下跌了 57.8%。</p>
</div><p>Before the market opened this morning, Embecta published results for the second quarter of its 2026 fiscal year -- which ended March 31. The company's sales and earnings for the period came in significantly weaker than expected, and investors aren't feeling optimistic about the near-term future.</p>
<div class="lb-trans"><p>今天早上市场开盘前，Embecta 发布了其 2026 财政年度第二季度的业绩——该季度于 3 月 31 日结束。公司的销售和收益显著低于预期，投资者对近期的未来并不乐观。</p>
</div><p><em><strong>Will AI create the world's first trillionaire?</strong> Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. <strong>Continue »</strong></em></p>
<div class="lb-trans"><p><em><strong>人工智能会创造出世界上第一个万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg2ODgwMi9nZXR0eWltYWdlcy0xODE4NTUxMzU5LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F868802%2Fgettyimages-1818551359.jpg&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>Embecta posted big misses in fiscal Q2</h2>
<div class="lb-trans"><h2>Embecta 在财政第二季度出现重大失误</h2>
</div><p>With its fiscal Q2 report, Embecta announced non-GAAP (adjusted) earnings per share of $0.27 on sales of $221.8 million. Meanwhile, the average analyst estimate had called for the business to record an adjusted profit of $0.42 per share on sales of roughly $235.7 million. Embecat's sales unexpectedly declined 14.4% year over year in fiscal Q2, and margins were significantly softer tahn anticipated. The company recorded an adjsuted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 29.1% in the quarter -- down from a margin of 37.5% in last year's quarter.</p>
<div class="lb-trans"><p>在财政第二季度的报告中，Embecta 宣布非公认会计原则（调整后）每股收益为 0.27 美元，销售额为 2.218 亿美元。同时，平均分析师预期该公司每股调整后利润为 0.42 美元，销售额约为 2.357 亿美元。Embecta 的销售额在财政第二季度意外下降了 14.4%，利润率也显著低于预期。该公司在本季度记录的调整后息税折旧摊销前利润（EBITDA）利润率为 29.1%——低于去年同期的 37.5%。</p>
</div><h2>What's on deck for Embecta?</h2>
<div class="lb-trans"><h2>Embecta 的未来展望</h2>
</div><p>With its fiscal Q2 report, Embecta lowered its full-year sales guidance to between $1.015 billion and $1.035 -- down from previous guidance for sales between $1.071 billion and $1.093 billion. The downward sales revision doesn'tlook massive, but it does raise questions about the company's near-term growth outlook.Meanwhile, the company's adjusted operating margin is now expected to be between 22.25% and 23.25% -- representing a substantial reduction from the previous guidance for a margin between 29% and 30% in the period.</p>
<div class="lb-trans"><p>在财政第二季度的报告中，Embecta 将全年的销售指导下调至 10.15 亿至 10.35 亿美元——低于之前的销售指导 1.071 亿至 1.093 亿美元。虽然销售下调幅度看似不大，但却引发了对公司近期增长前景的质疑。同时，该公司的调整后营业利润率现在预计在 22.25% 至 23.25% 之间——相比之前的 29% 至 30% 的指导大幅降低。</p>
</div><p>The company expects to close its acquisition of Owen Mumford and for the purchase to have a dilutive impact on earnings of roughly $0.15 per share. While acquisition-related expenses will present an earnings headwind, the company's move to lower guidance on adjusted earnings per share from between $2.80 and $3 to between $1.55 per share and $1.75 per share raises some big questions for investors.</p>
<div class="lb-trans"><p>该公司预计将完成对 Owen Mumford 的收购，并预计此次收购将对每股收益产生约 0.15 美元的稀释影响。虽然与收购相关的费用将对收益构成压力，但公司将调整后的每股收益指导从 2.80 至 3 美元下调至 1.55 至 1.75 美元，这对投资者提出了一些重大问题。</p>
</div><h2>Where to invest $1,000 right now</h2>
<div class="lb-trans"><h2>现在投资 1000 美元的地方</h2>
</div><p>When our analyst team has a stock tip, it can pay to listen. After all, <em>Stock Advisor’s</em> total average return is 963%* — a market-crushing outperformance compared to 201% for the S&amp;P 500.</p>
<div class="lb-trans"><p>当我们的分析师团队有股票推荐时，听取建议是值得的。毕竟，<em>Stock Advisor</em> 的总平均回报率为 963%*——相比标普 500 的 201% 表现出色。</p>
</div><p>They just revealed what they believe are the <strong>10 best stocks</strong> for investors to buy right now, <strong>available when you join_Stock Advisor._</strong></p>
<div class="lb-trans"><p>他们刚刚透露了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买，<strong>加入_Stock Advisor_ 时可获得。</strong></p>
</div><p><strong>See the stocks »</strong></p>
<div class="lb-trans"><p><strong>查看股票 »</strong></p>
</div><p><em>*Stock Advisor returns as of May 5, 2026.</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 的回报截至 2026 年 5 月 5 日。</em></p>
</div><p><em>Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Keith Noonan 在提到的任何股票中没有持仓。Motley Fool 在提到的任何股票中没有持仓。Motley Fool 有披露政策。</em></p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见是作者的观点和意见，并不一定反映纳斯达克公司的观点。</p>
</div>

为什么 Embecta 的股票今天大幅下跌